Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGILENT TECHNOLOGIES, INC.A · Entity 3062 | Sr. VP and CFO | May 22, 2025 | May 27, 2025 |
| ORASURE TECHNOLOGIES INCOSUR · Entity 6152 | Director | June 03, 2026 | June 05, 2026 |
| WEST PHARMACEUTICAL SERVICES INCWST · Entity 3201 | SVP & Chief Financial Officer | August 11, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGILENT TECHNOLOGIES, INC.
Report date May 22, 2025 · Filed May 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 168,753.746 |
Reported balance
After 2025-05-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-05-22 · Tax withholding · Disposed 3,499 · Balance 168,753.746 F1: The reporting person surrendered 3,499 shares to Agilent Technologies, Inc. to satisfy the tax liability on the vesting of restricted stock units in accordance with Rule 16b-3. F2: 61.314 shares acquired under the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person surrendered 3,499 shares to Agilent Technologies, Inc. to satisfy the tax liability on the vesting of restricted stock units in accordance with Rule 16b-3.
F2: 61.314 shares acquired under the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock.
ORASURE TECHNOLOGIES INC
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 123,137 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 46,106 · Balance 123,137 F1: Grant of restricted shares under the OraSure Technologies, Inc. Stock Award Plan, which shall vest in full upon the earlier of (i) June 3, 2027, or (ii) immediately prior to the commencement of the Company's 2027 Annual Meeting of Stockholders. Vesting shall cease immediately if the named individual voluntarily ceases to serve as a member of the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted shares under the OraSure Technologies, Inc. Stock Award Plan, which shall vest in full upon the earlier of (i) June 3, 2027, or (ii) immediately prior to the commencement of the Company's 2027 Annual Meeting of Stockholders. Vesting shall cease immediately if the named individual voluntarily ceases to serve as a member of the Board of Directors.
WEST PHARMACEUTICAL SERVICES INC
Report date August 11, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,020.506 |
Ending reported balance
After 2026-08-11 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-08-11 · Exercise / conversion · Acquired 794.469 · Balance 3,774.96 F1: Each restricted stock unit represents a contingent right to receive one share of WST common stock. Row 2 · 2026-08-11 · Tax withholding · Disposed 345.515 · Balance 3,429.445 Row 3 · 2026-08-11 · Exercise / conversion · Acquired 6,354.736 · Balance 9,784.181 F1: Each restricted stock unit represents a contingent right to receive one share of WST common stock. Row 4 · 2026-08-11 · Tax withholding · Disposed 2,763.675 · Balance 7,020.506 |
| Rst. Stock UnitSEC Table II · derivative / convertible security | Direct | 2,118.579 |
Reported balance
After 2026-08-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-11 · Exercise / conversion · Disposed 6,354.736 · Balance 2,118.579 F1: Each restricted stock unit represents a contingent right to receive one share of WST common stock. F2: On August 11, 2025, the reporting person was granted 12,670 restricted stock units, vesting in three installments - 4,223 shares (plus dividend equivalents) to vest six months from the grant date, 6,335 shares (plus dividend equivalents) to vest 12 months from the grant date and 2,112 shares (plus dividend equivalents) to vest 24 months from the grant date. |
| Rst. Stock UnitSEC Table II · derivative / convertible security | Direct | 2,383.4 |
Reported balance
After 2026-08-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-11 · Exercise / conversion · Disposed 794.469 · Balance 2,383.4 F1: Each restricted stock unit represents a contingent right to receive one share of WST common stock. F3: This award vests in four equal annual installments beginning on August 11, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of WST common stock.
F2: On August 11, 2025, the reporting person was granted 12,670 restricted stock units, vesting in three installments - 4,223 shares (plus dividend equivalents) to vest six months from the grant date, 6,335 shares (plus dividend equivalents) to vest 12 months from the grant date and 2,112 shares (plus dividend equivalents) to vest 24 months from the grant date.
F3: This award vests in four equal annual installments beginning on August 11, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
HOLOGIC INC
Report date August 02, 2018 · Filed August 03, 2018
Section 16 reporting ended · disclosed 2018-08-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 112,244 |
Reported balance
After 2018-08-02 transaction · row 1
1 source rowRow 1 · 2018-08-02 · Tax withholding · Disposed 7,699 · Balance 112,244 F1: Shares withheld for tax obligations relating to the settlement of deferred restricted stock units upon the Reporting Person's departure from the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld for tax obligations relating to the settlement of deferred restricted stock units upon the Reporting Person's departure from the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2026 Filed Aug 12, 2026 18:56 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionRst. Stock Unit · Derivative | 794.469 | $0.00 | $0.00 |
DisclosureSEC source: 0000105770-26-000104 · wk-form4_1786561008.xml · derivative · entry 6 McMahon Robert W. · CIK 0001608730 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,383.4 Underlying: Common Stock · 794.469 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of WST common stock. F3 · derivative.exercise_date: This award vests in four equal annual installments beginning on August 11, 2026. F3 · derivative.expiration_date: This award vests in four equal annual installments beginning on August 11, 2026. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 18:56 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionRst. Stock Unit · Derivative | 6,354.736 | $0.00 | $0.00 |
DisclosureSEC source: 0000105770-26-000104 · wk-form4_1786561008.xml · derivative · entry 5 McMahon Robert W. · CIK 0001608730 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,118.579 Underlying: Common Stock · 6,354.736 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of WST common stock. F2 · derivative.exercise_date: On August 11, 2025, the reporting person was granted 12,670 restricted stock units, vesting in three installments - 4,223 shares (plus dividend equivalents) to vest six months from the grant date, 6,335 shares (plus dividend equivalents) to vest 12 months from the grant date and 2,112 shares (plus dividend equivalents) to vest 24 months from the grant date. F2 · derivative.expiration_date: On August 11, 2025, the reporting person was granted 12,670 restricted stock units, vesting in three installments - 4,223 shares (plus dividend equivalents) to vest six months from the grant date, 6,335 shares (plus dividend equivalents) to vest 12 months from the grant date and 2,112 shares (plus dividend equivalents) to vest 24 months from the grant date. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 18:56 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 2,763.675 | $351.37 | $971,072.48 |
DisclosureSEC source: 0000105770-26-000104 · wk-form4_1786561008.xml · nonDerivative · entry 4 McMahon Robert W. · CIK 0001608730 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,020.506 Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 18:56 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 6,354.736 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000105770-26-000104 · wk-form4_1786561008.xml · nonDerivative · entry 3 McMahon Robert W. · CIK 0001608730 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,784.181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of WST common stock. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 18:56 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 345.515 | $351.37 | $121,403.61 |
DisclosureSEC source: 0000105770-26-000104 · wk-form4_1786561008.xml · nonDerivative · entry 2 McMahon Robert W. · CIK 0001608730 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,429.445 Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 18:56 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 794.469 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000105770-26-000104 · wk-form4_1786561008.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,774.96 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of WST common stock. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:03 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | GrantCommon Stock | 46,106 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000520 · form4.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,137 F1 · kind: Grant of restricted shares under the OraSure Technologies, Inc. Stock Award Plan, which shall vest in full upon the earlier of (i) June 3, 2027, or (ii) immediately prior to the commencement of the Company's 2027 Annual Meeting of Stockholders. Vesting shall cease immediately if the named individual voluntarily ceases to serve as a member of the Board of Directors. Read SEC document |
| May 13, 2026 Filed May 14, 2026 23:13 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Tax withholdingCommon Stock | 22,888 | $3.02 | $69,121.76 |
DisclosureSEC source: 0001470831-26-000437 · form4.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,031 F1 · kind: Withholding of shares to pay the tax liability associated with vesting of restricted shares. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 16:26 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Option (Right to Buy) · Derivative | 7,337 | $0.00 Strike: $254.34 | $0.00 |
DisclosureSEC source: 0000105770-26-000035 · form4.xml · derivative · entry 2 McMahon Robert W. · CIK 0001608730 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,337 Underlying: Common Stock · 7,337 shares Expires 2036-03-01 F3 · derivative.exercise_date: The stock option vests in four equal annual installments beginning on March 1, 2027. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 16:26 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantRst. Stock Unit · Derivative | 3,082 | $0.00 | $0.00 |
DisclosureSEC source: 0000105770-26-000035 · form4.xml · derivative · entry 1 McMahon Robert W. · CIK 0001608730 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,082 Underlying: Common Stock · 3,082 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of WST common stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2027. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2027. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 02:37 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionRst. Stock Unit · Derivative | 4,230.525 | $0.00 | $0.00 |
DisclosureSEC source: 0000105770-26-000007 · form4.xml · derivative · entry 3 McMahon Robert W. · CIK 0001608730 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,462.052 Underlying: Common Stock · 4,230.525 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On August 11, 2025, the reporting person was granted 12,670 restricted stock units, vesting in three installments - 4,223 shares (plus dividend equivalents) to vest six months from the grant date, 6,335 shares (plus dividend equivalents) to vest 12 months from the grant date and 2,112 shares (plus dividend equivalents) to vest 24 months from the grant date. F2 · derivative.expiration_date: On August 11, 2025, the reporting person was granted 12,670 restricted stock units, vesting in three installments - 4,223 shares (plus dividend equivalents) to vest six months from the grant date, 6,335 shares (plus dividend equivalents) to vest 12 months from the grant date and 2,112 shares (plus dividend equivalents) to vest 24 months from the grant date. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 02:37 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 1,250.034 | $246.16 | $307,708.37 |
DisclosureSEC source: 0000105770-26-000007 · form4.xml · nonDerivative · entry 2 McMahon Robert W. · CIK 0001608730 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,980.491 Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 02:37 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 4,230.525 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000105770-26-000007 · form4.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,230.525 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 23:19 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Option (Right to Buy) · Derivative | 7,137 | $240.33 Strike: $240.33 | $1,715,235.21 |
DisclosureSEC source: 0000105770-25-000074 · form4.xml · derivative · entry 4 McMahon Robert W. · CIK 0001608730 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,137 Underlying: Common Stock · 7,137 shares Expires 2035-08-11 F2 · derivative.exercise_date: This award vests in four equal installments beginning on August 11, 2026. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 23:19 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Option (Right to Buy) · Derivative | 7,647 | $240.33 Strike: $240.33 | $1,837,803.51 |
DisclosureSEC source: 0000105770-25-000074 · form4.xml · derivative · entry 3 McMahon Robert W. · CIK 0001608730 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,647 Underlying: Common Stock · 7,647 shares Expires 2035-08-11 F2 · derivative.exercise_date: This award vests in four equal installments beginning on August 11, 2026. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 23:19 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantRst. Stock Unit · Derivative | 3,168 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000105770-25-000074 · form4.xml · derivative · entry 2 McMahon Robert W. · CIK 0001608730 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,168 Underlying: Common Stock · 3,168 shares Expires not disclosed F2 · derivative.exercise_date: This award vests in four equal installments beginning on August 11, 2026. F2 · derivative.expiration_date: This award vests in four equal installments beginning on August 11, 2026. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 23:19 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantRst. Stock Unit · Derivative | 12,670 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000105770-25-000074 · form4.xml · derivative · entry 1 McMahon Robert W. · CIK 0001608730 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,670 Underlying: Common Stock · 12,670 shares Expires not disclosed F1 · derivative.exercise_date: This award vests in three installments. 4,223 shares will vest six months from the grant date, 6,335 shares will vest 12 months from the grant date, and 2,112 shares will vest 24 months from the grant date. F1 · derivative.expiration_date: This award vests in three installments. 4,223 shares will vest six months from the grant date, 6,335 shares will vest 12 months from the grant date, and 2,112 shares will vest 24 months from the grant date. Read SEC document |
| July 31, 2025 Filed Aug 4, 2025 20:58 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Tax withholdingCommon Stock | 7,317 | $3.21 | $23,450.99 |
DisclosureSEC source: 0001062993-25-013517 · form4.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,919 F1 · kind: Withholding of shares to pay the tax liability associated with vesting of restricted shares. Read SEC document |
| May 22, 2025 Filed May 27, 2025 18:43 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | Tax withholdingCommon Stock | 3,499 | $109.68 | $383,770.32 |
DisclosureSEC source: 0001127602-25-015623 · form4.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,753.746 F1 · shares: The reporting person surrendered 3,499 shares to Agilent Technologies, Inc. to satisfy the tax liability on the vesting of restricted stock units in accordance with Rule 16b-3. F2 · balance_after: 61.314 shares acquired under the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. Read SEC document |
| May 14, 2025 Filed May 15, 2025 20:46 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | GrantCommon Stock | 71,017 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-009565 · form4.xml · nonDerivative · entry 2 McMahon Robert W. · CIK 0001608730 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,236 F2 · kind: Grant of restricted shares under the OraSure Technologies, Inc. Stock Award Plan, which shall vest in full upon the earlier of (i) May 14, 2026, or (ii) immediately prior to the commencement of the Company's 2026 Annual Meeting of Stockholders. Vesting shall cease immediately if the named individual voluntarily ceases to serve as a member of the Board of Directors. Read SEC document |
| May 13, 2025 Filed May 15, 2025 20:46 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Tax withholdingCommon Stock | 6,427 | $2.65 | $17,047.62 |
DisclosureSEC source: 0001062993-25-009565 · form4.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,219 F1 · kind: Withholding of shares to pay the tax liability associated with vesting of restricted shares. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 22:15 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 5,385 | $126.51 | $681,256.35 |
DisclosureSEC source: 0001127602-25-008574 · form4.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,191.432 F1 · shares: Restricted Stock Units granted under the Agilent Technologies, Inc. 2018 Stock Plan, in compliance with Rule 16b-3. The restricted stock units will vest 100% at the 1-year anniversary of the grant date and are subject to a 1-year post-vest holding period. F2 · balance_after: 43.597 shares acquired under the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 23:43 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantEmployee Stock Option (Right to Buy) · Derivative | 18,544 | $138.14 Strike: $138.14 | $2,561,668.16 |
DisclosureSEC source: 0000950170-24-132367 · ownership.xml · derivative · entry 2 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,544 Underlying: Common Stock · 18,544 shares Expires 2034-11-27 F2 · security: Right to buy Agilent Technologies, Inc. common stock granted under the Agilent Technologies, Inc. 2018 Stock Plan, in compliance with Rule 16b-3. F3 · derivative.exercise_date: The option is exercisable in four equal annual installments beginning on the first anniversary of the date of the grant. The first vesting date is stated. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 23:43 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 6,423 | $138.14 | $887,273.22 |
DisclosureSEC source: 0000950170-24-132367 · ownership.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,762.835 F1 · shares: Restricted Stock Units granted under the Agilent Technologies, Inc. 2018 Stock Plan, in compliance with Rule 16b-3. The restricted stock units vest in four equal annual installments beginning on November 27, 2024 and are subject to a 1-year post-vest holding period. Read SEC document |
| November 22, 2024 Filed Nov 26, 2024 15:16 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | Tax withholdingCommon Stock | 5,775 | $133.84 | $772,926.00 |
DisclosureSEC source: 0001127602-24-028043 · form4.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,339.835 F1 · shares: The reporting person surrendered 5,775 shares to Agilent Technologies, Inc. to satisfy the tax liability on the vesting of restricted stock units in accordance with Rule 16b-3. Read SEC document |
| November 19, 2024 Filed Nov 22, 2024 00:47 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | Tax withholdingCommon Stock | 2,196 | $125.69 | $276,015.24 |
DisclosureSEC source: 0001127602-24-027862 · form4.xml · nonDerivative · entry 2 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,114.835 F2 · shares: The reporting person surrendered 2,196 shares to Agilent Technologies, Inc. to satisfy the tax liabilities on the vesting of restricted stock units in accordance with Rule 16b-3. Read SEC document |
| November 19, 2024 Filed Nov 22, 2024 00:47 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 7,835 | $125.69 | $984,781.15 |
DisclosureSEC source: 0001127602-24-027862 · form4.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,310.835 F1 · shares: On November 19, 2024, 7,835 shares of common stock of Agilent Technologies, Inc. were issued to the reporting person pursuant to the Agilent Technologies, Inc. Long-Term Performance Program. The shares are subject to a 1-year post-vest holding period. 2,350 shares were deferred pursuant to the Agilent Technologies, Inc. Deferred Compensation Plan. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 20:18 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | Tax withholdingCommon Stock | 1,295 | $127.07 | $164,555.65 |
DisclosureSEC source: 0001127602-24-027620 · form4.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,475.835 F1 · shares: The reporting person surrendered 1,295 shares to Agilent Technologies, Inc. to satisfy the tax liabilities on the vesting of restricted stock units in accordance with Rule 16b-3. F2 · balance_after: 171.4420 shares acquired under the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:50 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | GrantCommon Stock | 19,943 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-010489 · form4.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,646 F1 · kind: Grant of restricted shares under the OraSure Technologies, Inc. Stock Award Plan, which shall vest in full upon the earlier of (i) May 14, 2025, or (ii) immediately prior to the commencement of the Company's 2025 Annual Meeting of Stockholders. Vesting shall cease immediately if the named individual voluntarily ceases to serve as a member of the Board of Directors. Read SEC document |
| November 22, 2023 Filed Nov 27, 2023 18:16 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantEmployee Stock Option (Right to Buy) · Derivative | 20,734 | $123.99 Strike: $123.99 | $2,570,808.66 |
DisclosureSEC source: 0001127602-23-028268 · form4.xml · derivative · entry 3 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,734 Underlying: Common Stock · 20,734 shares Expires 2033-11-22 F3 · security: Right to buy Agilent Technologies, Inc. common stock granted under the Agilent Technologies, Inc. 2018 Stock Plan, in compliance with Rule 16b-3. F4 · derivative.exercise_date: The option is exercisable in four equal annual installments beginning on the first anniversary of the date of the grant. The first vesting date is stated. Read SEC document |
| November 22, 2023 Filed Nov 27, 2023 18:16 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 29,641 | $123.99 | $3,675,187.59 |
DisclosureSEC source: 0001127602-23-028268 · form4.xml · nonDerivative · entry 2 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,991.393 F2 · shares: Restricted Stock Units granted under the Agilent Technologies, Inc. 2018 Stock Plan, in compliance with Rule 16b-3. The restricted stock units vest beginning on November 22, 2023 in 3 installments, 33% at the 12-month anniversary of the grant, 33% at the 18-month anniversary of the grant and 34% at the 24-month anniversary of the grant and are subject to a 1-year post-vest holding period. Read SEC document |
| November 22, 2023 Filed Nov 27, 2023 18:16 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 7,312 | $123.99 | $906,614.88 |
DisclosureSEC source: 0001127602-23-028268 · form4.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,350.393 F1 · shares: Restricted Stock Units granted under the Agilent Technologies, Inc. 2018 Stock Plan, in compliance with Rule 16b-3. The restricted stock units vest in four equal annual installments beginning on November 22, 2023 and are subject to a 1-year post-vest holding period. Read SEC document |
| November 17, 2023 Filed Nov 20, 2023 23:04 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | Tax withholdingCommon Stock | 2,429 | $113.15 | $274,841.35 |
DisclosureSEC source: 0001127602-23-028019 · form4.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,038.393 F1 · shares: The reporting person surrendered 2,429 shares to Agilent Technologies, Inc. to satisfy the tax liability on the vesting of restricted stock units in accordance with Rule 16b-3. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 17:11 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | Tax withholdingCommon Stock | 504 | $114.19 | $57,551.76 |
DisclosureSEC source: 0001127602-23-027947 · form4.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,467.393 F1 · shares: The reporting person surrendered 504 shares to Agilent Technologies, Inc. to satisfy the tax liabilities on the vesting of restricted stock units in accordance with Rule 16b-3. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 18:31 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | Tax withholdingCommon Stock | 664 | $113.60 | $75,430.40 |
DisclosureSEC source: 0001127602-23-027747 · form4.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,971.393 F1 · shares: The reporting person surrendered 664 shares to Agilent Technologies, Inc. to satisfy the tax liability on the vesting of restricted stock units in accordance with Rule 16b-3. Read SEC document |
| November 14, 2023 Filed Nov 17, 2023 15:46 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | Tax withholdingCommon Stock | 4,248 | $111.61 | $474,119.28 |
DisclosureSEC source: 0001127602-23-027712 · form4.xml · nonDerivative · entry 2 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,635.393 F4 · shares: The reporting person surrendered 4,248 shares to Agilent Technologies, Inc. to satisfy the tax liability on the vesting of restricted stock units in accordance with Rule 16b-3. Read SEC document |
| November 14, 2023 Filed Nov 17, 2023 15:46 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 16,687 | $111.61 | $1,862,436.07 |
DisclosureSEC source: 0001127602-23-027712 · form4.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,883.393 F1 · shares: On November 14, 2023, 16,687 shares of common stock of Agilent Technologies, Inc. were issued to the reporting person pursuant to the Agilent Technologies, Inc. Long-Term Performance Program. The shares are subject to a 1-year post-vest holding period. 5,005 shares were deferred pursuant to the Agilent Technologies, Inc. Deferred Compensation Plan. F2 · balance_after: 138.56 shares acquired under the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. F3 · balance_after: Includes 0.387 shares acquired through revenue credit allocations relating to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan. The reporting person has elected to defer these shares of common stock. Read SEC document |
| November 14, 2023 Filed Nov 30, 2023 14:41 UTC Amendment | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | Tax withholdingCommon Stock | 4,640 | $111.61 | $517,870.40 |
DisclosureSEC source: 0001127602-23-028438 · form4a.xml · nonDerivative · entry 2 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,243.393 F4 · shares: The reporting person surrendered 4,640 shares to Agilent Technologies, Inc. to satisfy the tax liability on the vesting of restricted stock units in accordance with Rule 16b-3. Amended from the previous reported amount of 4,248 shares. Read SEC document |
| November 14, 2023 Filed Nov 30, 2023 14:41 UTC Amendment | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 16,687 | $111.61 | $1,862,436.07 |
DisclosureSEC source: 0001127602-23-028438 · form4a.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,883.393 F1 · shares: On November 14, 2023, 16,687 shares of common stock of Agilent Technologies, Inc. were issued to the reporting person pursuant to the Agilent Technologies, Inc. Long-Term Performance Program. The shares are subject to a 1-year post-vest holding period. 5,005 shares were deferred pursuant to the Agilent Technologies, Inc. Deferred Compensation Plan. F2 · balance_after: 138.56 shares acquired under the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. F3 · balance_after: Includes 0.387 shares acquired through revenue credit allocations relating to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan. The reporting person has elected to defer these shares of common stock. Read SEC document |
| July 31, 2023 Filed Aug 1, 2023 20:03 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | GrantCommon Stock | 22,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-015566 · form4.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,703 F1 · kind: Grant of restricted shares under the OraSure Technologies, Inc. Stock Award Plan, cliff vesting on July 31, 2025. Vesting shall cease immediately if the named individual voluntarily ceases to serve as a member of the Board of Directors. Read SEC document |
| November 18, 2022 Filed Nov 21, 2022 18:56 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | Tax withholdingCommon Stock | 1,750 | $146.19 | $255,832.50 |
DisclosureSEC source: 0001127602-22-026139 · form4.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,057.446 F1 · shares: The reporting person surrendered 1,750 shares to Agilent Technologies, Inc. to satisfy the tax liability on the vesting of restricted stock units in accordance with Rule 16b-3. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 15:53 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | Tax withholdingCommon Stock | 679 | $144.44 | $98,074.76 |
DisclosureSEC source: 0001127602-22-026118 · form4.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,807.446 F1 · shares: The reporting person surrendered 679 shares to Agilent Technologies, Inc. to satisfy the tax liability on the vesting of restricted stock units in accordance with Rule 16b-3. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 19:48 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | Tax withholdingCommon Stock | 504 | $147.12 | $74,148.48 |
DisclosureSEC source: 0001127602-22-026022 · form4.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,486.446 F1 · shares: The reporting person surrendered 504 shares to Agilent Technologies, Inc. to satisfy the tax liability on the vesting of restricted stock units in accordance with Rule 16b-3. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 14:45 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantEmployee Stock Option (Right to Buy) · Derivative | 15,661 | $148.00 Strike: $148.00 | $2,317,828.00 |
DisclosureSEC source: 0001127602-22-025885 · form4.xml · derivative · entry 4 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,661 Underlying: Common Stock · 15,661 shares Expires 2032-11-15 F4 · security: Right to buy Agilent Technologies, Inc. common stock granted under the Agilent Technologies, Inc. 2018 Stock Plan, in compliance with Rule 16b-3. F5 · derivative.exercise_date: The option is exercisable in four equal annual installments beginning on the first anniversary of the date of the grant. The first vesting date is stated. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 14:45 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | Tax withholdingCommon Stock | 11,380 | $148.00 | $1,684,240.00 |
DisclosureSEC source: 0001127602-22-025885 · form4.xml · nonDerivative · entry 3 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,990.446 F3 · shares: The reporting person surrendered 11,380 shares to Agilent Technologies, Inc. to satisfy the tax liability on the vesting of restricted stock units in accordance with Rule 16b-3. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 14:45 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 32,134 | $148.00 | $4,755,832.00 |
DisclosureSEC source: 0001127602-22-025885 · form4.xml · nonDerivative · entry 2 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,370.446 F2 · shares: On November 15, 2022, 32,134 shares of common stock of Agilent Technologies, Inc. were issued to the reporting person pursuant to the Agilent Technologies, Inc. Long-Term Performance Program. The shares are subject to a 1 year post-vest holding period. 9,640 shares were deferred pursuant to the Agilent Technologies, Inc. Deferred Compensation Plan. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 14:45 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 5,359 | $148.00 | $793,132.00 |
DisclosureSEC source: 0001127602-22-025885 · form4.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,236.446 F1 · shares: Restricted Stock Units granted under the Agilent Technologies, Inc. 2018 Stock Plan, in compliance with Rule 16b-3. The restricted stock units vest in four equal annual installments beginning on November 15, 2022 and are subject to a 1 year post-vest holding period. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 22:42 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | Tax withholdingCommon Stock | 1,860 | $148.31 | $275,856.60 |
DisclosureSEC source: 0001127602-22-025643 · form4.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,877.446 F1 · shares: The reporting person surrendered 1,860 shares to Agilent Technologies, Inc. to satisfy the tax liability on the vesting of restricted stock units in accordance with Rule 16b-3. F2 · balance_after: 14.663 shares acquired under the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. F3 · balance_after: Includes 1.578 shares acquired through revenue credit allocations relating to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan. The reporting person has elected to defer these shares of common stock. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 15:38 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | Tax withholdingCommon Stock | 2,303 | $134.56 | $309,891.68 |
DisclosureSEC source: 0001127602-22-020519 · form4.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,721.205 F1 · shares: The reporting person surrendered 2,303 shares to Agilent Technologies, Inc. to satisfy the tax liabilities on the vesting of restricted stock units in accordance with Rule 16b-3. F2 · balance_after: 47.205 shares acquired under the Agilent Technologies, Inc. dividend reinvestment plan. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 18:05 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | Tax withholdingCommon Stock | 1,751 | $164.30 | $287,689.30 |
DisclosureSEC source: 0000899243-21-045720 · doc4.xml · nonDerivative · entry 1 McMahon Robert W. · CIK 0001608730 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,977 F1 · shares: The reporting person surrendered 1,751 shares to Agilent Technologies, Inc. to satisfy the tax liability on the vesting of restricted stock units in accordance with Rule 16b-3. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.